Dublin Academic Medical Centre Summer School 2009
|
|
- Muriel Craig
- 6 years ago
- Views:
Transcription
1 Health Care Economics Dublin Academic Medical Centre Summer School 2009 Peter Carney UCD Geary Institute UCD School of Economics UCD Geary Institute University College Dublin Belfield, Dublin 4 Ireland geary@ucd.ie Institiúid Geary UCD, An Coláiste Ollscoile, Baile Átha Cliath, Belfield, Baile Átha Cliath 4, Eire
2 Healthcare Economics & Economic Evaluation Overview of Economist s Perspective Introduction to the Principles Economic Evaluation of Healthcare Suite of Tools A Guide to Critical Assessment (10 point)
3 Introduction to economic analysis in health care Health economics is the application of economic theory, models and empirical techniques to the analysis of decision-making by individuals, health care providers and governments with respect to health and health care It offers a unique and systematic intellectual framework for analysing important issues in health care. This is useful since the healthcare sector consumes a great deal of resources, and because the organisation and delivery of health care is influenced by the economic environment and economic conditions.
4 Is health care an economic good? An economic good is any good or service that is scarce relative to our wants for it. Heath care is an economic good because the resources that are used to produce health care services are finite. More resources can be devoted to the production and consumption of health care only by diverting them form some other use. Health care is an economic good because our wants for health care have no known bounds No health care system has achieved levels of spending sufficient to meet all its citizens wants for health care
5 Overview of Economist s Perspective So in essence, resources time, labour, facilities, equipment, knowledge are limited. We do not have the resources to satisfy all the goods and services that we desire. Resources spent on one item cannot be spent on another. This gives rise to the concept of Opportunity Cost; the value of the best forgone alternative. In a real sense, the cost of any programme is not the s in the budget sheet but rather the health outcomes from the programme which has been forgone by committing the resources in question to the first programme.
6 Overview of Economist s Perspective Economic evaluations are not concerned with accounting costs, financial management and cost-cutting. Concern is with the comparative analysis of alternative courses of action in terms of both their cost and consequences to make the best use of available resources. The ultimate aim of healthcare evaluation is the choosing of programmes that maximise benefits for society from society s resources.
7 2. Economic Evaluation of Healthcare Economic evaluations as a tool for healthcare assessment and cost-effectiveness in particular. Drummond et al. (2005) - Economic Evaluation of Health Care Programmes.
8 The Suite of Tools Cost-minimisation analysis Cost-effectiveness analysis Cost-consequences analysis Cost-utility analysis Cost-benefit analysis The four tools value consequences by assuming them either as equivalent (CMA), in some natural unit (CEA), in multiple natural units (CCA), in derived utilities (CUA), or in monetary units (CBA).
9 Economic Evaluations in Healthcare Each approach is acceptable so long as it is appropriately justified. The ultimate choice will depend on the context and the specific question posed. Gold (1996) the models are not mutually exclusive forms of analysis; the use of one does not exclude the use of another in any one study Furthermore, CUA and CBA can generally be retrospectively applied to CEA with further work. Especially if outcome measures lend themselves to utility assessment (to be valued) In general the majority of evaluations in healthcare are CEA
10 Critical Assessment A guide to critically assessing economic evaluations will give you a sharp appreciation of the most important aspects of evaluations and a sense of the standard that is expected in the literature. We will look at these aspects by asking 10 core questions that will allow you to Recognise well conducted evaluations Assess the validity of the results you encounter Open up a chest of literature on previous evaluations carried out in your field and their utility in your work
11 Checklist for economic evaluation 1. Was a well-defined question posed in an answerable form? A well specified question for example might look as follows: From the viewpoint of (a) both the ministry of health and the ministry of social welfare budgets (b) patients incurring out-ofpocket costs, is treatment X preferable to the existing programme of treatment Z in (i) reducing symptom, (ii) preventing infection, (iii) increasing QALYs, (iv) increasing life years saved, (v) reducing mortality? Bad Questions e.g. Will a community hypertension programme do any good? This solicits the wrong answer. Similarly questions such as How much does it cost to run our intensive care unit? are NOT efficiency questions as they fail to specify the alternatives for comparison. The answers to questions such as these do not themselves qualify as efficiency statements.
12 2. Was a comprehensive description of the competing alternatives given? Were relevant alternatives omitted? Can you tell who did what to whom, where, and how often Was a do-nothing alternative considered? A clear and specific statement of the primary objective of each alternative programme, treatment, or service is critical in appropriately selecting costeffectiveness analysis, cost-utility analysis, or cost benefit analysis (CEA, CUA and CBA, respectively) as the type of evaluation to be undertaken. A full description of the alternatives is essential for three further reasons.
13 2. Comprehensive description of the competing alternatives I 1. Readers must be able to judge the applicability of the programmes to their own settings. 2. Readers should be able to assess for themselves whether any costs or consequences may have been omitted in the analysis 3. Readers may wish to replicate the programme procedures being described.
14 3. Was the effectiveness of the programmes or services established? Was this done through a randomized controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?! Were effectiveness data collected and summarised through a systematic overview of clinical studies? If so, were the search strategy and rules for inclusion or outlined? Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?
15 3. Establishing effectiveness of the programme or service We are not interested in an ineffective services, that is, a service which have been shown to do no more good than harm (by themselves, or compared with no treatment). We are not interested in the provision of such services under any other conditions, efficient or otherwise, if something is not worth doing its not worth doing well!! Therefore if the economic evaluation assumes effectiveness some indication of the validation of effectiveness should be given.
16 4. Were all the important and relevant costs and consequences for each alternative identified? Was the range wide enough for the research questions sat hand? Did it cover all relevant viewpoints? Possible viewpoints include the community or social viewpoint, and those of patients and third-party payers. Were capital costs, as well as operating cots, included? Even though it may not be possible or necessary to measure and value all of the costs and consequences of the alternatives under comparison, a full identification of the important and relevant ones should be provided. The combination of information contained in the viewpoint statement and programme description should allow judgement of what specific costs and consequences or outcomes it is appropriate to include in the analysis.
17 5. Were costs and consequences measured accurately in appropriate physical units? Hours of nursing time, number of physician visits, lost work days, gained life years. Were the sources of resource utilization described and justified? Were any of the identified items omitted from the measurement? If so, does this mean that they carried no weight in the subsequent analysis? Were there any special circumstances (for example, joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?
18 5. Identification and appropriate measurement of costs and consequences While identification, measurement and valuation often occur simultaneously in analyses, it is a good practice for users of evaluation results to view each as a separate phase of analysis. Once the important costs and consequences have been identified they must be measures in appropriate physical and natural units. E.g. measurement of the operating costs of a particular screening programme may yield a partial list of ingredients such as 500 physical examinations performed by physicians, 10 weeks of salaried nursing time, 10 weeks of a 1000 square foot clinic, 20 hours of medical research librarian time from an adjoining hospital and so on.. Similarly, costs borne by patients may be measured, by the amount of medication purchased, the number of times travel was required for treatment or time lost from work for treatment.
19 A note on Costs: per unit costs Overhead costs like housekeeping or central administration are allocated to various departments on the basis of some measure judged to be related to usage of the overhead item (e.g., square feet of floor space). Analyst needs to judge how important this cost is an then assign the appropriate effort and care to estimating it accurately. Average per diem cost may often suffice one can improve on this by stripping these costs of their medical component leaving the hotel component of the hospital expenditure for which all patients can be assumed equal so cost can be ascribed on the number of patient-days. Allows for medical care cost to be estimated separately ~ benefit is that these key costs can directly relate to the specific patients in the programme.
20 Levels of precision in hospital costing Most Precise Least precise Micro-costing Each component of resource use (for example, laboratory tests, days of stay by wards, drugs) is estimated and a unit cost derived for each. Case- mix group Gives the cost for each category of case or hospital patient. Takes account of length of stay. Precision depends on the level of detail in specifying the types of cases. Disease- specific per diem( or daily cost) Gives the average daily cost for treatments in each disease category. These may still be quite broad( for example, orthopaedic surgery) Average per diem (or daily cost) Averages the per diem over all categories of patient. Available in most health care systems.
21 Outcomes Examples of effectiveness measures used in CEAs in the published literature: Hypertension ~ mmhg Bp reduction Hypercholesterolemia ~ % serum cholesterol reduction Asthma ~ Episode-free day Thrombolysis ~ Life years gained Some are final, health-related measures of outcome, such as lifeyears gained or episode-free days. Others are expressed as intermediate outcomes, such as percentage cholesterol reduction or cases detected. The most important issue to consider is whether the measure is relevant, given the objectives of the decision maker concerned. As more jurisdiction request economic evaluation as part of the formal decision making process for health technologies, measures that relate to broader objectives, such as maximizing health gain, are becoming most relevant.
22 How does one link intermediate and final outcomes? Although intermediate outcomes may themselves have some value (or clinical meaning), the economic analyst should ideally choose an effectiveness measure relating to a final outcome. In some cases, where the size of the relative risk (for example, of death) comparing individuals with and without the risk factor is large, it may be possible to establish the link through observational or case-control studies. An example here is a link between smoking and lung cancer. However, when undertaking a CEA using effectiveness data relating to an intermediate endpoint the analyst should either Make a case for the intermediate endpoint having value or clinical relevance in its own right Be confident that the link between intermediate and final outcomes has been adequately established by previous research or, Ensure that any uncertainty surrounding the link is adequately characterized in the economic study.
23 6. Were costs and consequences valued credibly? Were the sources of all values clearly identified? (Possible sources include market values, patient or client preferences and views, policymakers views and health professionals judgements.) Were market values employed for changes involving resources gained or depleted? The sources of methods of valuation of costs, benefits and utilities should be clearly stated in the economic evaluation. Costs are normally valued in units of local currency, based on prevailing prices of, for example, personnel, commodities, and services, and can often be taken directly from programme budgets. All current and future programme costs are normally valued in constant Euros of some base year (usually the present), in order to remove effects of inflation from the analysis.
24 7. Were costs and consequences adjusted for differential timing? Were costs and consequences that occur in the future discounted to their present values? Was any justification given in the discount rate used? Because comparison of programmes or services must be made at one point in time (usually the present), the timing of programme costs and consequences that do not occur entirely in the present must be taken into account. Different programmes may have different time profiles of costs and consequences e.g. the primary benefits of the influenza immunization programme are immediate while those of hypertension screening occur well into the future.
25 8. Was an incremental analysis of costs and consequences alternatives performed? Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits or utilities generated? For meaningful comparison, it is necessary to examine the additional coats that one service or programme imposes over another, compared with the additional effects, benefits, or utilities it delivers. Table 3.1 shows the costs and outcomes (in terms of direct diagnoses) generated by two alternative strategies: impendence plethysmography (IPG) alone versus IPG plus outpatient venography if impendence plethysmography is negative.
26 Economic evaluation of alternative diagnostic strategies for 516 patients with clinically suspected deep-vein thrombosis. Programme Cost ($) Outcome (number Of correct diagnoses) 1. IPG (alone) Ratio of cost to outcome ($ per correct diagnoses) 2. IPG plus out patient venography if IPG negative 3. Increment (of programme 2 over programme 1)
27 9. Was allowance made for the uncertainty in the estimates of costs and consequences? If patient level data on costs or consequences were available, were appropriate statistical analyses performed? If sensitivity analysis was employed, was justification provided for the ranges or distributions of values (for hey study parameters), and the form of sensitivity analysis used? Were the conclusions of the study sensitive to the uncertainty in the result, as quantified by the statistical and/or sensitivity analysis?
28 10. Did the presentation and discussion of study results include all issues of concern to users? Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (for example, cost-effectiveness ratio)? If so, was the index interpreted intelligently or in mechanistic fashion? Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology? Did the study allude to, or take account of, other important factors in the choice or decision under consideration for example, distribution of costs and consequences, or relevant ethical issues?) Did the study discuss issues of implementation, such as the feasibility of adopting the preferred programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?
29 How might effectiveness data to be obtained? A major source of effectiveness data is the existing medical literature. Use of such data in economic evaluation raise three issues Quality Relevance Comprehensiveness
30 Assessing medical literature A full discussion of appraising the quality of medical evidence is beyond the scope of this talk.. generally, economists support the quality criteria laid down by clinical epidemiologists for clinicians seeking evidence to support clinical recommendations. It is rare for the data on clinical outcomes used in economic evaluations to be drawn solely from clinical trials. In judging the relevance of results published in the literature, one would have to consider how close one s own situation is to those where the published clinical studies were conducted. Important factors to consider are the patient case-load, the expertise of medical and other staff, and the existence of back-up facilities. The third criterion for judging effectiveness evidence in economic evaluation is comprehensiveness. That is, are the clinical data used in the economic evaluation representative of the medical literature as a whole?
31 Nowadays, many more economic evaluations use data from a review of clinical trials and well-conducted synthesis of available data. Finally, in situations where no good clinical evidence exists, the cost effectiveness analysts may proceed by making assumptions about the clinical evidence and then undertaking a sensitivity analysis of the economic results to different assumptions. The underlying logic is that if the final result is not sensitive to the estimate used for a given variable, then it is not worth much effort to obtain a more accurate estimate.
32 Note: Evaluations cost money themselves! They should be carried out efficiently. Costing can take considerable time and effort and one shouldn t make the perfect the enemy of good. Therefore, analysts need to make judgements on how accurate (or precise) cost estimates need to be within a given study. In general, the analyst will need to judge the importance of different costs and consequences in the overall scheme and work accordingly; any important assumptions made should be included in the discussion.
Economic Evaluations of Social Care Interventions: Are we all on the same page?
Economic Evaluations of Social Care Interventions: Are we all on the same page? Helen Weatherly 1, Rita Faria 1, Mark Sculpher 1, Peter O Neill 2 ( 1 Centre for Health Economics, 2 NICE) This work was
More informationMethodological Finding; and Principles
3 Methodological Finding; and Principles Contents Introduction..................................................... Methodological Limitations.......................................... Weaknesses Inherent
More informationThis is an author produced version of The UK NHS Economic Evaluation Database : Economic issues in evaluations of health technology.
This is an author produced version of The UK NHS Economic Evaluation Database : Economic issues in evaluations of health technology. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/593/
More informationTOOL #47. EVALUATION CRITERIA AND QUESTIONS
TOOL #47. EVALUATION CRITERIA AND QUESTIONS 1. INTRODUCTION All evaluations and fitness checks should assess the evaluation criteria of effectiveness, efficiency, coherence, relevance and EU added value
More informationAUSTRALIAN ENGINEERING COMPETENCY STANDARDS STAGE 2 - EXPERIENCED PROFESSIONAL ENGINEER IN LEADERSHIP AND MANAGEMENT
AUSTRALIAN ENGINEERING COMPETENCY STANDARDS STAGE 2 - EXPERIENCED IN LEADERSHIP AND MANAGEMENT The Stage 2 Competency Standards are the profession's expression of the knowledge and skill base, engineering
More informationHuman Research Protection Program Guidance for Human Research Determination
Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects
More informationThe use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer
TECHNOLOGY ASSESSMENT REPORTS FOR THE HTA PROGRAMME The use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer A. Final version. B. Details of review team ScHARR Assessment Team
More informationCHAPTER 2. Conceptual Framework for Financial Reporting 9, 10, 11, 30 6, Basic assumptions. 12, 13, 14 5, 7, 10 6, 7
CHAPTER 2 Conceptual Framework for Financial Reporting ASSIGNMENT CLASSIFICATION TABLE (BY TOPIC) Topics Questions Brief Exercises Exercises Concepts for Analysis 1. Conceptual framework general. 2. Objectives
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationA Guide for Assessing Health Research Knowledge Translation (KT) Plans
A Guide for Assessing Health Research Knowledge Translation (KT) Plans Developed as part of a research study being conducted by investigators from the Centre for Addiction and Mental Health and McMaster
More informationSchool of Economics and Management LIUC University, Castellanza, Italy
Stefano Capri School of Economics and Management LIUC University, Castellanza, Italy scapri@liuc.it ISPOR Issue Panel, Dublin SESSION IV, Wednesday, 6 November 2013 What should health economists, from
More informationWho s in good health? Measuring performance in the NHS
Agenda Advancing economics in business Who s in good health? Measuring performance in the NHS Public spending on healthcare has increased significantly over the past five years. One way to assess the benefits
More informationPreparing a Cost- Benefit Analysis for TEAM. Dale Dilamarter November 7, 2011
Preparing a Cost- Benefit Analysis for TEAM Dale Dilamarter November 7, 2011 Who am I? Business Advisor to TEAM Available to discuss business issues related to all TEAM projects CHEE 310 Fundamentals of
More informationScottish Medicines Consortium
Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF) (Revised June 2007) Part A: General guidance for completion of the NPAF Part B: Guidance for
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationClinical Commissioning Policy: Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant
Clinical Commissioning Policy: Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant January 2014 Reference: NHS ENGLAND A07/P/c NHS England Clinical Commissioning
More informationPAPER No. : 02 MANAGERIAL ECONOMICS MODULE No. : 03 PRINCIPLES: INDIVIDUAL AND MARKET
Subject Paper No and Title Module No and Title Module Tag 02: Managerial Economics 03: Principles: Individual and Market COM_P2_M3 TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction 3. Principles-
More informationCrowe Critical Appraisal Tool (CCAT) User Guide
Crowe Critical Appraisal Tool (CCAT) User Guide Version 1.4 (19 November 2013) Use with the CCAT Form version 1.4 only Michael Crowe, PhD michael.crowe@my.jcu.edu.au This work is licensed under the Creative
More informationAnnual Performance Report Scorecard Evaluation Criteria
Annual Performance Report Scorecard Evaluation Criteria The purpose of the Mercatus Center s assessment of federal agencies annual performance reports is to ascertain how well agency reports inform the
More informationMAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief
MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE 1 1.0 INTRODUCTION Cancer Research UK (CRUK) believes cancer patients should have access to the best, evidence-based innovative
More informationCurrent Trends at FDA: Implications for Data Requirements
Introduction The environment surrounding medical device regulation in the United States has always been rigorous, but recent events including well-publicized quality issues associated with implantable
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationComposite Performance Measure Evaluation Guidance. April 8, 2013
Composite Performance Measure Evaluation Guidance April 8, 2013 Contents Introduction... 1 Purpose... 1 Background... 2 Prior Guidance on Evaluating Composite Measures... 2 NQF Experience with Composite
More information1) Operating costs, such as fuel and labour. 2) Maintenance costs, such as overhaul of engines and spraying.
NUMBER ONE QUESTIONS Boni Wahome, a financial analyst at Green City Bus Company Ltd. is examining the behavior of the company s monthly transportation costs for budgeting purposes. The transportation costs
More informationChallenges of Analytical Method Transfer in the Pharmaceutical Industry
Challenges of Analytical Method Transfer in the Pharmaceutical Industry White Paper Author: Steve Alley, Technical Specialist 1 Contents Introduction 2 Method Transfer Team 3 Identify Methods 4 Gap Analysis
More informationMental health clinical costing
Mental health clinical costing standards 2016/17 shaping healthcare finance Clinical costing standards Contents Foreword 3 Introduction 4 Standard 1: Classification of direct, indirect and overhead costs
More informationExternal Audit: Annual Audit Letter
INFRASTRUCTURE, GOVERNMENT AND HEALTHCARE External Audit: Annual Audit Letter 2005-06 Southport and Ormskirk Hospital NHS Trust September 2006 AUDIT Content The contacts at KPMG in connection with this
More informationCOUNTY DURHAM & DARLINGTON NHS FOUNDATION TRUST
COUNTY DURHAM & DARLINGTON NHS FOUNDATION TRUST Introduction County Durham and Darlington NHS Foundation Trust is one of the largest integrated care providers in England, serving a population of around
More informationCODE OF PRACTICE FOR RESEARCH
CODE OF PRACTICE FOR RESEARCH Dr Diana Leighton REF Manager Professor Andy Young Director of Research & Innovation Services Version 1.0 - September 2010 First approved Academic Board 27 September 2010
More informationGuidelines for the Economic Evaluation of Health Technologies: Canada
CADTH METHODS AND GUIDELINES Guidelines for the Economic Evaluation of Health Technologies: Canada 4th Edition Service Line: CADTH Methods and Guidelines Version: 1.0 Publication Date: March 2017 Report
More informationAchieve. Performance objectives
Achieve Performance objectives Performance objectives are benchmarks of effective performance that describe the types of work activities students and affiliates will be involved in as trainee accountants.
More informationChapter 1. Introduction
Chapter 1 You must have already been introduced to a study of basic microeconomics. This chapter begins by giving you a simplified account of how macroeconomics differs from the microeconomics that you
More informationWHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs
Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends
More informationThe methods to estimate the monetary value of the environment
The methods to estimate the monetary value of the environment Dr. Alberto Longo Department of Economics and International Development University of Bath A.Longo@bath.ac.uk 1 Overview of the presentation
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Medical Technologies Evaluation Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Medical Technologies Evaluation Programme Sponsor submission of evidence: Evaluation title: Sponsor: Date sections A and B submitted: Date section C submitted:
More informationINTEGRATED WATER RESOURCES MANAGEMENT
DEPARTMENT OF WATER AFFAIRS AND FORESTRY INTEGRATED WATER RESOURCES MANAGEMENT GUIDELINES FOR WATER CONSERVATION AND WATER DEMAND MANAGEMENT IN WATER MANAGEMENT AREAS AND IN THE WATER SERVICES SECTOR,
More informationNICE Guidelines: A Methodological Basis for Decision Making. Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham
NICE Guidelines: A Methodological Basis for Decision Making Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham Pre Meeting Symposium - ISPOR Annual Conference Washington
More informationECONOMICS 103. Dr. Emma Hutchinson, Fall 2017
ECONOMICS 103 Dr. Emma Hutchinson, Fall 2017 http://web.uvic.ca/~ehutchin/teach/103/103f17.html Reminder: familiarize yourself with all course policies by reading the course outline and all posted info.
More informationQualification Specification 601/3688/1 icq Level 3 Diploma in Management (RQF)
Qualification Specification 601/3688/1 icq Level 3 Diploma in Management (RQF) Qualification Details Title : icq Level 3 Diploma in Management (RQF) Awarding Organisation : ican Qualifications Limited
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationOpportunities in the Health Care Practice at Analysis Group
Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice
More informationWorking Party on Aid Evaluation
For Official Use DCD/DAC/EV(2001)3 DCD/DAC/EV(2001)3 For Official Use Organisation de Coopération et de Développement Economiques Organisation for Economic Co-operation and Development 24-Apr-2001 English
More informationAdaptive Design for Medical Device Development
Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationUCU guidance on workload risk assessments in FE
UCU guidance on workload risk assessments in FE This factsheet is intended to help UCU reps in FE make the case to their employers on how to conduct risk assessments on workload and excessive working hours
More informationAS Economics. Introductory Microeconomics. Sixth Form pre-reading
AS Economics Introductory Microeconomics Sixth Form pre-reading The economic problem Economics is a social science which studies how humans behave when faced by the economic problem of scarcity. Economic
More informationDATA QUALITY POLICY. Version: 1.2. Management and Caldicott Committee. Date approved: 02 February Governance Lead
DATA QUALITY POLICY Version: 1.2 Approved by: Date approved: 02 February 2016 Name of Originator/Author: Name of Responsible Committee/Individual: Information Governance, Records Management and Caldicott
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationOCR Economics AS-level
OCR Economics AS-level Microeconomics Topic 1: Scarcity and Choice 1.1 The basic economic problem Notes Economic and free goods Economic goods benefit society, have the problem of scarcity and have an
More informationDISCUSSION OF COST BENEFIT ANALYSIS By Silva Ecosystem Consultants Ltd. Revised February 1996
DISCUSSION OF COST BENEFIT ANALYSIS By Silva Ecosystem Consultants Ltd. Revised February 1996 This document may be reproduced or distributed freely and without charge, provided said reproduction is not
More informationEthical Principles in Clinical Research
Ethical Principles in Clinical Research Christine Grady NIH Clinical Center Department of Bioethics No conflicts of interest. Views presented are mine and do not necessarily represent positions or policies
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationGUIDELINE. Methods for health economic evaluations. Final version. May 2015
GUIDELINE Methods for health economic evaluations - A guideline based on current practices in Europe Final version May 2015 Copyright EUnetHTA 2013. All Rights Reserved. No part of this document may be
More informationModules for Accounting and Finance
Modules for Accounting and Finance Modules, other than Introductory modules may have pre-requisites or co-requisites (please, see module descriptions below) and a student must have undertaken and passed
More informationMARKETING (MKT) Marketing (MKT) 1
Marketing (MKT) 1 MARKETING (MKT) MKT 201. Foundations of Marketing. 3 Credit Understanding and satisfying consumer need through product planning, pricing, promotion, and distribution. Students identify
More informationLast Update: 7-Jul-15 Outcome-based Specification Guide
Healthcare Supply Chain Network (HSCN) Innovation Procurement Outcome-based Specification Guide Last Update: 7-Jul-15 Outcome-based Specification Guide Table of contents Introduction... 3 Purpose of this
More informationA Guide for Developing Health Research Knowledge Translation (KT) Plans
A Guide for Developing Health Research Knowledge Translation (KT) Plans Adapted from: A Guide for Assessing Health Research Knowledge Translation Plans 2007 A Guide for Assessing Health Research Knowledge
More informationResources for occupational health are scarce. 1,2 Therefore, decision
ORIGINAL ARTICLE Trial-Based Economic Evaluations in Occupational Health Principles, Methods, and Recommendations Johanna M. van Dongen, MSc, Marieke F. van Wier, PhD, Emile Tompa, PhD, Paulien M. Bongers,
More informationRegional Genomics Service Improvement Lead Job Description and Person Specification
Regional Genomics Service Improvement Lead Job Description and Person Specification Position Job title Regional Genomics Service Improvement Lead Directorate Medical Directorate Pay band AFC Band 8d Responsible
More informationIntroduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics
PART Introduction 1 1 Why Technicians Need to Study Pharmacology and Therapeutics 2 Pharmacokinetics Understanding Pharmacology for Pharmacy Technicians 1 CHAPTER 1 Why Technicians Need to Study Pharmacology
More informationCustomer Lifetime Value Modelling
Rhino Risk Customer Lifetime Value Modelling Alan Lucas Rhino Risk Ltd. 1 Purpose of Talk To discuss the Customer Value paradigm, explaining how it can be used to optimize customer-level decisions Key
More informationHSE HR Circular 001/ th January 2014
Oifig an Stiúrthóra Náisiúnta, Acmhainní Daonna Feidhmeannacht na Seirbhísí Sláinte Ospidéal Dr. Steevens Baile Átha Cliath 8 Office of the National Director of Human Resources Health Service Executive
More informationOther issues for Volume 2 of the revised SEEA
LG/15/6 15 th Meeting of the London Group on Environmental Accounting Wiesbaden, 30 November 4 December 2009 Other issues for Volume 2 of the revised SEEA Peter Comisari OTHER ISSUES FOR VOLUME 2 OF THE
More informationEvaluation, Evaluators, and the American Evaluation Association
Evaluation, Evaluators, and the American Evaluation Association What is evaluation? Evaluation is a field that applies systematic inquiry to help improve programs, products, and personnel, as well as the
More informationCIPS Exam Report for Learner Community:
CIPS Exam Report for Learner Community: Qualification: Professional diploma in procurement and supply Unit: PD5 - Programme and project management Exam series: Nov 2016 Each element of a question carries
More informationProgress in the measurement of public sector output and productivity in the UK since the Atkinson Review
STATISTICS DIRECTORATE National Accounts and Financial Statistics Division Progress in the measurement of public sector output and productivity in the UK since the Atkinson Review This document will be
More informationAid Program Monitoring and Evaluation Standards
Aid Program Monitoring and Evaluation Standards Valid from April 2014 to April 2015 Table of Contents Introduction Standard 1: Investment Design (required features for M&E) 5 Standard 2: Initiative Monitoring
More informationBENEFIT-COST ANALYSIS Financial and Economic Appraisal using Spreadsheets
BENEFIT-COST ANALYSIS Financial and Economic Appraisal using Spreadsheets Ch. 12: Valuation of Non-marketed Goods Harry Campbell & Richard Brown School of Economics The University of Queensland We have
More information3410N Assurance engagements relating to sustainability reports
3410N Assurance engagements relating to sustainability reports Royal NIVRA 3410N ASSURANCE ENGAGEMENTS RELATING TO SUSTAINABILITY REPORTS Introduction Scope of this Standard ( T1 and T2) 1. This Standard
More informationPOLICY AND PROCEDURE JOB EVALUATION POLICY
POLICY AND PROCEDURE JOB EVALUATION POLICY Reference Number: 124 2007 Author / Manager Responsible: Peter Eley, HR Manager & AfC Project Manager Deadline for ratification: (Policy must be ratified within
More informationWorkbook table of contents
Management Training Course www.elitetraining.co.uk This is an extract of some sections from our project management workbook. We work with you to agree the full, relevant, contents. Workbook table of contents
More informationUnit: CPC 415 Assess required outcomes and specify a sustainable supply of services (Commissioning, Procurement and Contracting)
Unit: CPC 415 Assess required outcomes and specify a sustainable supply of services (Commissioning, Procurement and Contracting) Key Purpose The key purpose identified for those working in commissioning,
More informationApplied Welfare Economics
Economics Monika Köppl - Turyna Department of Economics ISCTE-IUL Summer 2014/2015 Introduction We will have lectures and problem solving sessions (usually one per two lectures) Attendance is generally
More informationCasework Technical Support (Social Welfare - Project Management)
Casework Technical Support (Social Welfare - Project Management) Request for Tenders for Services to MABS NATIONAL DEVELOPMENT The latest date for receipt of tenders is 09 June 2017 Commercial House Westend
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationTerms of Reference. Quality and Value Audits
Terms of Reference Quality and Value Audits Table of Contents SECTION 1 General 3 1.1 Introduction 3 1.2 Statutory authority 3 1.3 Purpose and Scope 4 SECTION 2 Methodology 6 2.1 The audit programme 6
More informationFOUNDATIONS IN ACCOUNTANCY Paper FAU (UK) Foundations in Audit (United Kingdom)
Answers FOUNDATIONS IN ACCOUNTANCY Paper FAU (UK) Foundations in Audit (United Kingdom) June 2012 Answers Section A QUESTIONS 1 10 MULTIPLE CHOICE Question Answer See Note Below 1 A 1 2 D 2 3 C 3 4 B 4
More informationConsumer Choice and Demand. Chapter 9
Consumer Choice and Demand Chapter 9 Lecture Outline Applying The Standard Budget Constraint Model Two Additional Demand Shifters Time and Coinsurance Issues in Measuring Health Care Demand Impacts of
More informationAn Examination of New Theories on Price Effects of Cross-Market Hospital Mergers
An Examination of New Theories on Price Effects of Cross-Market Hospital Mergers David A. Argue and Lona Fowdur 1 Economists Incorporated, Washington, DC Traditionally, mergers that involve combinations
More informationFinancial Strategy 2012
UNIVERSITY OF STIRLING Financial Strategy 2012 jn12 This document presents a revised and updated financial strategy for the University of Stirling. It defines what a financial strategy is and how it fits
More informationOrganisational Change Policy and Procedure
Organisational Change Policy & Procedure Document Type Author Owner (Dept) Organisational Change Policy and Procedure Senior Management Team Human Resources Date of Review July 2013 List of Contents Page
More informationBenefit-cost analysis and decision-making under risk uncertainty: issues and illustrations
Interdisciplinary Perspectives on Drinking Water Risk Assessment and Management (Proceedings of the Santiago (Chile) Symposium, September 1998). IAHS Publ. no. 260, 2000. 141 Benefit-cost analysis and
More informationWhite Paper. Benefits and Value
Benefits and Value The only purpose of undertaking any business activity is to create value! If undertaking the work destroys value the activity should not be started. Any value proposition though is in
More informationNational Biosecurity Capability Network. Biosecurity Response Operations: Team Member
Job Description Workstream Reports to Approved by National Biosecurity Capability Network New Zealand building one team capable of dealing with any biosecurity emergency Team Member Team Manager Andrea
More informationMyeloma UK Policy Working with the Pharmaceutical Industry
Policy Working with the Pharmaceutical Industry Background The relationship between patient organisations and the pharmaceutical industry has come under increasing scrutiny in recent times, with the media
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationStandards of proficiency. Biomedical scientists
Standards of proficiency Biomedical scientists Contents Foreword 1 Introduction 3 Standards of proficiency 7 Foreword We are pleased to present the Health and Care Professions Council s standards of proficiency
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More informationResearch: Ethics, Informed Consent, FDA, Off Label Use
Research: Ethics, Informed Consent, FDA, Off Label Use Nasim Hedayati, MD, FACS, RPVI Assistant Professor Division of Vascular and Endovascular Surgery University of California, Davis 2015 Phlebology Review
More informationAn Introductory Guide. For Clinicians & Service Managers CAPACITY FOR PSYCHOLOGICAL THERAPIES SERVICES. By The Mental Health Collaborative
An Introductory Guide For Clinicians & Service Managers CAPACITY FOR PSYCHOLOGICAL THERAPIES SERVICES By The Mental Health Collaborative 01/02 Introduction This guide provides a basic introduction to capacity
More informationQUALIFICATION HANDBOOK
QUALIFICATION HANDBOOK Level 4 NVQ Diploma in Spectator Safety Management (6852-04) October 2011 Version 1.0 Qualification at a glance Subject area City & Guilds number 6852 Spectator Safety Age group
More informationISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1
Epidemiologic Research 1 December 12, 2006 Comments on 2006 CIOMS draft Special Ethical Considerations for Epidemiologic Research as proposed supplement to the updated 2002 CIOMS International Ethical
More informationInstitute of Risk Management. IRM s CPD scheme 2016
Institute of Risk Management IRM s CPD scheme 2016 About IRM IRM is the leading professional body for enterprise risk management. We are an independent, not-for-profit organisation that champions excellence
More informationFlorida State University Policy 7-IRB-
Florida State University Policy 7-IRB- Title of Policy: Institutional Review Board Jurisdiction/Applicability Responsible Executive: Gary K. Ostrander Approving Official: Gary K. Ostrander Effective Date:
More informationIT S TIME! PRIMARIS OPERATIONAL EFFICIENCY SOLUTION. Using Lean Thinking to Save Time & Money. Benefits of Operational Efficiency. Why Primaris?
IT S TIME! PRIMARIS OPERATIONAL EFFICIENCY SOLUTION Using Lean Thinking to Save Time & Money Healthcare executives are well aware that both government agencies and private insurers are moving away from
More informationTHE COSTS AND BENEFITS OF DIVERSITY
Fundamental rights & anti-discrimination THE COSTS AND BENEFITS OF DIVERSITY European Commission Emplo 2 THE COSTS AND BENEFITS OF DIVERSITY A Study on Methods and Indicators to Measure the Cost-Effectiveness
More informationWriting a business case
Writing a business case A how to guide for Heads/Directors/Leaders/Mangers of Midwifery Birthrate Plus Associates 1.0 Introduction Congratulations on the completion of your Birthrate Plus assessment. If
More information